Microdose, Author at Microdose

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Industry

27 Dec 2021

PharmaTher Provides Update on Pipeline and Milestones for 2022

PharmaTher is one of the psychedelic medicine industry’s best kept secrets....

By Microdose

Events

26 Dec 2021

PsyCap Recap: H.C. Wainwright Takes a Look at the Markets

Mr....

By Microdose

Industry

24 Dec 2021

Tryp Therapeutics Announces Advancement of Phase 2a Clinical Trial

The company announced today the receipt of correspondence from the U....

By Microdose

Culture

21 Dec 2021

Psychedelic Holiday Giving Guide

With the holiday season upon us we thought it’d be a good time to discuss giving....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Press Releases

17 Dec 2021

BLACKHAWK GROWTH ANNOUNCES PLAN TO SPIN-OUT PSYCHEDELIC SUBSIDIARIES AND PROPOSES 1:1 DISTRIBUTION RATIO

The company will undertake a spin-out transaction whereby the shares of its wholly owned subsidiaries MindBio Therapeutics Pty....

By Microdose

Industry

17 Dec 2021

MindMed Initiates Phase 2a LSD Trial

MindMed begins its Phase 2a trial using LSD to treat ADHD...

By Microdose

Industry

14 Dec 2021

atai Life Sciences Added to NASDAQ Biotechnology Index

Atai announced it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective as of market open on Monday, December 20, 2021...

By Microdose

Psychedelic Titans

9 Dec 2021

Psychedelic Titans with Neil Gehani of Mindlumen

This week's Psychedelic Titan is Neil Gehani, Founder of Mindlumen....

By Microdose

Psychedelic Titans

2 Dec 2021

Psychedelic Titans with Larry Zeifman of Zeifmans LLP

This week's Psychedelic Titan is Larry Zeifman, Partner for Zeifmans LLP....

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts

WordPress Ads

No Result

View All Result

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Industry

PharmaTher Provides Update on Pipeline and Milestones for 2022

Events

PsyCap Recap: H.C. Wainwright Takes a Look at the Markets

Industry

Tryp Therapeutics Announces Advancement of Phase 2a Clinical Trial

Culture

Psychedelic Holiday Giving Guide

Join Our Newsletter for Exclusive Updates, Stories, and More

Press Releases

BLACKHAWK GROWTH ANNOUNCES PLAN TO SPIN-OUT PSYCHEDELIC SUBSIDIARIES AND PROPOSES 1:1 DISTRIBUTION RATIO

Industry

MindMed Initiates Phase 2a LSD Trial

Industry

atai Life Sciences Added to NASDAQ Biotechnology Index

Psychedelic Titans

Psychedelic Titans with Neil Gehani of Mindlumen

Psychedelic Titans

Psychedelic Titans with Larry Zeifman of Zeifmans LLP

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

Delix Therapeutics Reports Strong Phase Ib Results

Childhood Trauma’s Role in Men’s Substance Use Disorders

Human-Centered AI in Healthcare

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch